Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Jan 06, 2020

Dean Hakanson co-wrote this blog post with Ed Schoonveld. This blog post was originally published on The Price of Global Health.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

Trump’s Drug Pricing Plan: What Does it Really Mean for Pharma?

Posted by Pratap Khedkar on Wed, Jul 04, 2018

Howard Deutsch co-authored this blog post with Pratap Khedkar.

President Donald Trump and HHS Secretary Alex Azar addressed the nation from the White House Rose Garden last week, introducing American Patients First, a drug pricing plan that Pres. Trump described as the “most sweeping action in history to lower the price of prescription drugs.” Let’s take a closer look, shall we?


>
Read More

Five Observations From the 2017 Fair Pricing Forum

Posted by Ed Schoonveld on Mon, May 15, 2017

In May, I joined various members of governmental organizations, patient organizations and the life sciences industry at the 2017 Fair Pricing Forum, an invitation-only meeting to discuss “fair pricing” for medications in Amsterdam. Organized by the World Health Organization and the Dutch Ministry of Health, the meeting prompted a productive dialogue among stakeholders but also revealed a worrisome gap in the overall perception of the drug pricing discussion. The pharmaceutical industry’s viewpoint was widely underrepresented, with attendance heavily weighted toward governments and activists, and only a small industry delegation.


>
Read More